Difficult blood pressure control: Watch out for non-compliance!

Nephrology Dialysis Transplantation

Volumn 18, Issue 10, 2003, Pages 1969-1973

  Wuerzner, Kaisa ^a   Hassler, Christophe ^a   Burnier, Michel ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Division of Nephrology   (Switzerland)

Author keywords

Compliance; Methods; Monitoring; Resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG USE; EDITORIAL; HEALTH CARE COST; HEART FAILURE; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MONITOR; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; ATTITUDE TO HEALTH; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK ASSESSMENT; SWITZERLAND; TREATMENT REFUSAL;

EID: 0141730389     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg281     Document Type: Editorial

References (27)

1. Chalmers J, MacMahon S, Mancia G et al. WHO/ISH Hypertension Guidelines Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-185
2. Burt VL, Cutler JA, Higgins M et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995; 26: 60-69
3. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747-752
4. Smith WC, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rules of halves. Br Med J 1990; 300: 981-983
5. Banegas JR, Rodriguez-Artalejo F, de la Cruz Troca JJ, Guallar-Castillon P, del Rey Calero J. Blood pressure in Spain: distribution, awareness, control and benefits of a reduction in average pressure. Hypertension 1998; 32: 998-1002
6. Ibrahim MM, Rizk H, Appel LJ et al. Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP). Hypertension 1995; 26: 886-890
7. Astagneau P, Lang T, Delarocque E, Jeannee E, Salem G. Arterial hypertension in urban Africa: an epidemiological study on a representative sample of Dakar inhabitants in Senegal. J Hypertens 1992; 10: 1095-1101
8. Chen CH, Lin HC, Kuo HS, Chang MS, Chou P. Epidemiology of hypertension in Kin-Hu, Kinmen. Am J Hypertens 1995; 8: 395-403
9. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. J Am Med Assoc 2002; 18: 2981-2997
11. Berlowitz DR, Ash AS, Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-1963
12. Oliveira SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch S. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413-420
13. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians. Blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000; 160: 2281-2286
14. Fagard RH, Ven den Enden, Leeman M, Warling X. Survey on treatment of hypertension and implementation of WHO/ISH risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297-1302
15. Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive treatment the role of adverse effects and compliance. Blood Press 1998; 7: 313-315
16. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordination Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446
17. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. Br Med J 2001; 323: 142-146
18. Fallab-Stubi CL, Zellweger JP, Sauty A, Uldry C, Iorillo D, Burnier M. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998; 2: 525-530
19. Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin treatment in family practice. Can Med Assoc J 1980; 123: 119-122
20. Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens 2003; 21 [Suppl 2]: S37-S42
21. Urquhart J. The electronic medication event monitoring. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 245-256
22. Burnier M, Schneider MP, Chioléro A, Fallab-Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rationale therapeutic decisions. J Hypertens 2001; 19: 335-341
23. Bertholet N, Favrat B,.Fallab-Stubi C. L, Brunner H.R, Burnier M. Why objective monitoring of compliance is important for the management of hypertension. J Clin Hypertens 2000; 2: 258-261
24. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive treatment. Int J Clin Pract 1999; 53: 37-38
25. Mallion JM, Dutrey-Dupagne C, Vaur L et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens 1996; 14: 137-144
26. Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 2002; 59: 65-94
27. Urquhart J. Some economic consequences of noncompliance. Curr Hypertens Rep 2001; 3: 473-480